Andrew Zolopa

Clinical Trials

• Not Recruiting Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
• Recruiting Consent for Use of Stored Patient Specimens for Future Testing
• Recruiting Long-Term Data Collection From Participants in Adult AIDS Clinical Trials
• Not Recruiting HIV Prevention and Care of Psychological Trauma in Vulnerable Rwandan Youth
• Not Recruiting Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
• Not Recruiting Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
• Not Recruiting Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
• Not Recruiting Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
• Not Recruiting A Comparative Study of Aleglitazar and Actos® in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.
• Not Recruiting Sevelamer for Reducing Endotoxemia and Immune Activation
• Not Recruiting Safety and Efficacy of T Cell Genetic Immunotherapy for HIV
• Recruiting Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults
• Recruiting Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
• Recruiting Rifaximin as a Modulator of Microbial Translocation and Immune Activation
• Recruiting Evaluating the Effectiveness of the Quadrivalent Human Papillomavirus (HPV) Vaccine at Preventing Anal HPV Infection in HIV-Infected Men and Women
• Recruiting Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors
• Recruiting High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART
• Recruiting Stanford Universities: The Stanford HIV Aging Cohort
• Recruiting Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen